Clinical Trials Browser

Phase 2 × INDUSTRY × GSK2110183 × Clear all

NCT01531894 2019-07-09

Continuation Study of the Oral AKT Inhibitor GSK2110183

Phase 2 Completed

11 enrolled 8 charts

Other hematologic neoplasm

Neoplasms, Hematologic Neoplasms

NCT01445587 2012-03-26

A Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple Myeloma

Phase 2 Withdrawn

Other hematologic neoplasmPlasma cell

Multiple Myeloma, Neoplasms, Hematologic Neoplasms